Cargando…
Severe Prolonged SGLT2i-induced Euglycemic Diabetic Ketoacidosis Refractory to Standard Therapy and Dialysis: Case Report and Literature Review
Sodium-glucose cotransporter type 2 inhibitors (SGLT2i) are oral hypoglycemic agents that have insulin-independent glucose-lowering effects mediated by increasing the renal excretion of glucose by inhibiting the SGLT2-mediated renal glucose reabsorption. An increasingly recognized complication induc...
Autores principales: | Almazrouei, Raya, Alkindi, Fatima, Alshamsi, Aisha, Dawoud, Tasnim, Chaaban, Ahmad, Rahman, Masood Ur |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
OMJ
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9188737/ https://www.ncbi.nlm.nih.gov/pubmed/35712376 http://dx.doi.org/10.5001/omj.2022.17 |
Ejemplares similares
-
Clinical Characteristics and Outcomes of Diabetic Ketoacidosis in
Patients With Type 2 Diabetes using SGLT2 Inhibitors
por: Almazrouei, Raya, et al.
Publicado: (2023) -
Euglycemic Diabetic Ketoacidosis With SGLT-2 Inhibitor
por: Manas, F N U, et al.
Publicado: (2021) -
THU389 Euglycemic Diabetic Ketoacidosis With Prolonged Ketosis Due To SGLT-2 Inhibitor
por: Viera Feliciano, Natalia, et al.
Publicado: (2023) -
Euglycemic diabetic ketoacidosis in the era of SGLT-2 inhibitors
por: Chow, Erica, et al.
Publicado: (2023) -
Euglycemic Diabetic Ketoacidosis after Discontinuing SGLT2 Inhibitor
por: Alhemeiri, Mohamed, et al.
Publicado: (2022)